Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 80

Inclusion Criteria

1. Female or male pediatric patient aged 2 to 17 years,
2. Patient with known or suspected lesion(s) scheduled to undergo routine contrast-enhanced MRI of CNS or of other organs including at least one organ among head and neck, thorax, abdomen, pelvis and musculoskeletal system (including extremities),
3. Patient whose parent(s) or legal guardian (where applicable) having read the information provided his/her/their consent to patient’s participation in writing by dating and signing the informed consent prior to any trial related procedure being conducted,
4. Patient with capacity of understanding who received age- and maturity-appropriate information and provided his/her assent to participate in the trial (as required by national regulations),
5. Patient affiliated to national health insurance according to local regulatory requirements.
Are the trial subjects under 18? yes
Number of subjects for this age range: 80
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1.Patient planned for treatment or procedure (e.g. surgery) that would prevent from obtaining the required blood samples or performing other trial procedures between the screening visit and up to 1 day after gadopiclenol administration,
2.Patient undergoing treatment or procedure (e.g., diuretics, clinically significant blood loss or blood transfusion) preceding or subsequent to gadopiclenol administration that would alter gadopiclenol pharmacokinetic parameters,
3.Patient with acute or chronic renal insufficiency defined as estimated Glomerular Filtration Rate (eGFR) out of age-adjusted normal ranges [eGFR must be calculated based on bedside Schwartz equation],
4.Patients referred for MR Angiography.
5.Patient with history of bleeding disorder,
6.Patient with known severe liver disease,
7.Patient with known cardiac disease (e.g., heart rhythm anomalies, long QT syndrome),
8.Patient with any clinically significant abnormal 12-lead ECG that in the Investigator's opinion would affect the safety evaluation or place the patient at risk,
9.Patient with electrolyte or fluid imbalance that at Investigator’s judgment presents undue risk assessed within 1 month prior to gadopiclenol administration,
10.Patient undergoing a change in chemotherapy within 1 day prior to or 1 day after gadopiclenol administration,
11.Patient who received or will receive any other contrast agent for CT and/or MRI within 1 week prior to or 1 week after gadopiclenol administration,
12.Patient with contraindication for MRI such as iron metal implants (e.g., aneurysm clips, pacemaker),
13.Patient with history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents,
14.Patient with history of hypersensitivity caused by any contrast media / agents (iodinated or gadolinium-based),
15.Patient with known contraindication(s) to the use of any gadolinium-based contrast agent (GBCA),
16.Pregnant or breast-feeding female patient [female patient with childbearing potential (who experienced menarche) must have a negative urine pregnancy test within 24 hours prior to gadopiclenol administration and must be using medically approved contraception* if sexually active],
17.Patient with anticipated, current or past condition (medical, psychological, social or geographical) that would compromise the patient’s safety or her/his ability to participate to the whole trial,
18.Patient unlikely to comply with the protocol, e.g., uncooperative attitude of parent(s) or legal guardian (where applicable), inability to return for follow-up visits and unlikelihood of completing the trial,
19.Having participated in a clinical trial and having received any investigational product within 7 days prior to gadopiclenol administration or planned during the trial,
20.Patient previously included in this trial,
21.Patient related to the Investigator or any other trial staff or relative directly involved in the trial conduct.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials